share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外國發行人報告
美股SEC公告 ·  04/29 18:18
牛牛AI助理已提取核心訊息
Alterity Therapeutics, a biotechnology company, announced new data on its lead drug candidate ATH434 at the World Orphan Drug Congress USA 2024 on April 29, 2024. The data presented suggests ATH434's potential as an iron chaperone to treat Friedreich’s Ataxia, a rare neurodegenerative disease. Unlike traditional iron chelators, ATH434 is designed to redistribute iron within the body rather than remove it. This could address the pathology of diseases like Friedreich’s Ataxia by reducing labile iron levels and slowing disease progression. The study, presented by Ashley Pall from Wayne State University, highlighted ATH434's unique iron-targeting properties and its lower affinity for ferric iron compared to traditional chelators. ATH434 has completed Phase 1 studies and is currently in two Phase 2 clinical trials for Multiple System Atrophy (MSA), with Orphan drug designation granted by the U.S. FDA and the European Commission for MSA treatment. The announcement was authorized by CEO David Stamler and the poster presentation is available on Alterity's website.
Alterity Therapeutics, a biotechnology company, announced new data on its lead drug candidate ATH434 at the World Orphan Drug Congress USA 2024 on April 29, 2024. The data presented suggests ATH434's potential as an iron chaperone to treat Friedreich’s Ataxia, a rare neurodegenerative disease. Unlike traditional iron chelators, ATH434 is designed to redistribute iron within the body rather than remove it. This could address the pathology of diseases like Friedreich’s Ataxia by reducing labile iron levels and slowing disease progression. The study, presented by Ashley Pall from Wayne State University, highlighted ATH434's unique iron-targeting properties and its lower affinity for ferric iron compared to traditional chelators. ATH434 has completed Phase 1 studies and is currently in two Phase 2 clinical trials for Multiple System Atrophy (MSA), with Orphan drug designation granted by the U.S. FDA and the European Commission for MSA treatment. The announcement was authorized by CEO David Stamler and the poster presentation is available on Alterity's website.
生物技術公司Alterity Therapeutics於2024年4月29日在美國2024年世界孤兒藥大會上公佈了其主要候選藥物 ATH434 的新數據。提供的數據表明，ATH434 有可能作爲鐵伴侶治療弗裏德賴希共濟失調，這是一種罕見的神經退行性疾病。與傳統的鐵螯合劑不同，ATH434 旨在將鐵重新分配到體內，而不是將其去除。這可以通過降低不穩定的鐵水平和減緩疾病進展來解決弗裏德賴希共濟失調等疾病的病理問題。這項研究由韋恩州立大學的阿什利·帕爾提出，強調了 ATH434 獨特的鐵靶向特性，以及與傳統螯合劑相比，它對鐵的親和力較低。ATH434 已經完成了 1 期研究，目前正在進行兩項多系統萎縮 (MSA) 的 2 期臨床試驗，MSA 治療由美國食品藥品管理局和歐盟委員會授予孤兒藥資格。該公告已獲得首席執行官戴維·斯塔姆勒的授權，海報展示可在Alterity的網站上公佈。
生物技術公司Alterity Therapeutics於2024年4月29日在美國2024年世界孤兒藥大會上公佈了其主要候選藥物 ATH434 的新數據。提供的數據表明，ATH434 有可能作爲鐵伴侶治療弗裏德賴希共濟失調，這是一種罕見的神經退行性疾病。與傳統的鐵螯合劑不同，ATH434 旨在將鐵重新分配到體內，而不是將其去除。這可以通過降低不穩定的鐵水平和減緩疾病進展來解決弗裏德賴希共濟失調等疾病的病理問題。這項研究由韋恩州立大學的阿什利·帕爾提出，強調了 ATH434 獨特的鐵靶向特性，以及與傳統螯合劑相比，它對鐵的親和力較低。ATH434 已經完成了 1 期研究，目前正在進行兩項多系統萎縮 (MSA) 的 2 期臨床試驗，MSA 治療由美國食品藥品管理局和歐盟委員會授予孤兒藥資格。該公告已獲得首席執行官戴維·斯塔姆勒的授權，海報展示可在Alterity的網站上公佈。
有用
沒用

該公告為獨立文件：

獨立文件1

獨立文件2

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。